Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cystic Fibrosis Market Snapshot: Disease-Modifying Drugs Elusive 24 Years After Discovery Of Root Cause

Executive Summary

The discovery in 1989 of the underlying genetics causing cystic fibrosis was expected to spur broad development of disease-modifying therapies. As of 2013, however, only one such drug is on the market, for a small subset of CF patients, and a few other candidates are in clinical development.

You may also be interested in...

Beyond Orkambi: Cystic Fibrosis Pipeline Includes Other Genetic, Symptomatic Therapy Approaches

PTC Therapeutics looks to offer drug therapy for nonsense mutation CF patients, while Corbus is developing an anti-inflammatory, antifibrotic drug that it hopes will benefit the entire CF patient population.

Corbus Believes A Different Inflammation-Fighting Approach Will Serve All CF Patients

The start-up asserts that agonizing the CB2 receptor will “resolve” inflammation, a different approach than used by anti-inflammatory drugs, and one that would pertain to the entire cystic fibrosis patient population.

U.K.’s Verona Explores Cystic Fibrosis Role For Novel Bronchodilator

A U.K. patient charity will fund preclinical studies of RPL554 for cystic fibrosis, Verona’s lead compound already in development for another niche respiratory condition, COPD exacerbations.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts